医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Bionic Vision Australia Successfully Completes Clinical Trial of Implant in Retinitis Pigmentosa

2014年09月30日 PM11:00
このエントリーをはてなブックマークに追加


 

MELBOURNE, Australia

Bionic Vision Australia (BVA), a consortium of researchers working together to develop bionic eye devices to restore a sense of vision to people with profound vision loss, today announced the successful completion of the first clinical trial of its prototype 24-channel percutaneous implant in patients with profound vision loss from the eye disease retinitis pigmentosa (RP). RP is an inherited, degenerative eye disease that causes severe vision impairment and often blindness through progressive degeneration of the retina and death of the photoreceptors.

The two year Prototype 24-Channel Percutaneous Connector Study, which started in May 2012, involved three RP patients with profound vision loss (bare light perception only) who each received surgically-implanted suprachoroidal electrode implants to aid the restoration of vision. Surgery was completed without any adverse events.

During the two year study, the implants were remarkably stable, with no significant movement, and were shown to be safe with no unexpected device-related serious adverse events observed. Although this was designed to be primarily a proof-of-concept and safety study, the trial also generated efficacy data showing that the device improved patient’s ability to see light and shapes, and helped with navigation around obstacles and detection of items on a tabletop search task.

“This study is critically important to the continuation of our research efforts and the results exceeded all our expectations,” Professor Mark Hargreaves, Chair of the BVA board, commented. “We have demonstrated clearly that our suprachoroidal implants are safe to insert surgically and cause no adverse events once in place. Significantly, we have also been able to observe that our device prototype was able to evoke meaningful visual perception in patients with profound visual loss.”

With this study complete, BVA has three other programs underway. The first of these, a 44-channel device will enter the clinic in mid-2015. The consortium is also developing a 98-channel device and a high acuity device.

BVA will be available to discuss this study at the AdvaMed2014 conference in Chicago on 6-8 October http://advamed2014.com/.

A full press kit with background information and images can be found at: https://app.box.com/s/bq9jt8g1uvs014dex84s

About Bionic Vision Australia

Bionic Vision Australia is a national consortium of researchers working together to develop bionic eye devices to restore a sense of vision to people with profound vision loss due to retinitis pigmentosa and age-related macular degeneration. The consortium includes researchers from the Bionics Institute, the Centre for Eye Research Australia, National ICT Australia, the University of Melbourne and the University of New South Wales with additional project partners including The National Vision Research Institute, the University of Western Sydney and the Royal Victorian Eye and Ear Hospital. Bionic Vision Australia is an initiative of the Australian Research Council. The project brings together a cross-disciplinary group of world-leading experts in the fields of ophthalmology, biomedical engineering, electrical engineering and materials science, neuroscience, vision science, psychophysics, wireless integrated-circuit design, and surgical, preclinical and clinical practice. Further information can be found at www.bionicvision.org.au.

CONTACT

Company:
Bionic Vision Australia
Dr. Julia Hill,
+313-502-7276
hill.j[at]unimelb.edu.au
or
Australian
Media:

Instinctif Partners
Dr. Douglas Pretsell, +61
(0)466-925-966
douglas.pretsell[at]instinctif.com
or
U.S.
Media:

Dawn Fallon, +646-871-8481
dfallon[at]lazarpartners.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Clover Biopharmaceuticals Completes RMB 62.8 Million Series A Financing
  • 三叶草生物制药完成6,280万元人民币A轮融资
  • Corindus Announces First Commercial Installation of CorPath® GRX System Outside of U.S.
  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表